CD19 antibody and other CD marker antibodies: buy the clone, not the CD number

Choosing the reagent for the marker

1. Buy the clone, not the CD number. The antigen is defined by the CD nomenclature and the reagent is defined by the clone. Published panels cite clones for that reason, and substituting a different clone against the same antigen is a change that has to be re-titrated and re-validated rather than assumed equivalent.
2. Know what each marker actually resolves. CD45 separates leucocytes from everything else and is the usual backbone of a panel. CD19 marks B cells, CD3e marks T cells, CD14 marks monocytes and CD68 marks macrophages, largely intracellularly. CD44 is broadly expressed and is a state marker rather than a lineage one, which is why it needs a quantitative rather than a positive or negative reading.
3. Match the format to the assay. A clone selected against native surface protein for flow cytometry may not work on a fixed section, and an antibody validated for immunohistochemistry may not stain live cells. Read the evidence per application rather than the application list, and buy against the assay you will run.
4. Titrate every conjugate on your own sample. The datasheet dilution came from somebody else's cells and buffer. Run a dilution series and choose the concentration giving the best separation between positive and negative, which is frequently several times more dilute than recommended and always cheaper.
5. Assign brightness against abundance across the panel. Put the brightest fluorochromes on the least abundant antigens. A very bright conjugate on an abundant marker like CD45 spreads into neighbouring detectors and costs resolution on the markers that needed it.

Fixation and permeabilisation change the answer, as for a CD68 antibody

Surface markers are stained on live or lightly fixed cells; an intracellular marker such as CD68 needs permeabilisation, and the permeabilisation that works for a cytoplasmic protein is not the one that works for a nuclear one. Choose the buffer system for the hardest marker in the panel.

Test the surface markers under the permeabilisation conditions the panel will use. Several surface epitopes are damaged by the harsher permeabilisation reagents, and the loss looks like poor staining rather than a protocol problem.

Controls that make a gate defensible

A viability dye, an unstained control, single stained compensation controls on the same carrier as the experiment, and a fluorescence minus one control for any marker whose gate is not obvious. The last of those is the one most often skipped and the one that decides where a boundary sits.

For a study running over months, a frozen reference sample run with every batch is what separates instrument and reagent drift from biology.

Recording the panel so it can be rebuilt

Marker, clone, conjugate, supplier, catalogue number, lot and the titrated volume per test. A panel recorded as a list of colours cannot be reproduced when a reagent is discontinued, which happens more often than people plan for.

Keep the titration data with the panel record. When a new lot arrives, the previous titration curve is the fastest way to see whether anything has moved.

Therapeutic clones, signalling chains and mouse panels

Several clones in routine research use share a target, and sometimes a lineage, with a therapeutic antibody. That makes them useful as positive controls and as blocking reagents, and it does not make a research-grade vial equivalent to a clinical product: the formulation, the endotoxin specification and the release testing are different, and only the research use is supported.

It also means the clone may be functional rather than inert. A clone that engages its receptor can activate the cell it is meant to be counting, which shows up as a changed phenotype during staining. Where phenotyping is the job, choose a clone characterised as non-activating and titrate it.

Signalling chains live inside the cell

Some components of a surface receptor complex are entirely intracellular, so they cannot be stained without permeabilisation and they report assembly rather than surface expression. Reading such a stain as a surface marker is a category error, and it appears in panels more often than it should.

In engineered cells the same reagents are used to confirm that a construct is expressed and correctly assembled. That is a legitimate and different use, and it needs an untransduced control processed identically so the background from the endogenous protein is visible.

Mouse panels in treated animals

When an animal has been dosed with an antibody against a surface marker, the marker may be occupied, internalised or shed, and a staining reagent against the same epitope will report a loss that is not a loss of cells. Use a clone binding a different epitope, and include an untreated animal in the same run.

The same caution applies to any experiment where a blocking antibody is used in vivo and a phenotype is read afterwards by flow cytometry. Stating which epitope each reagent binds is what makes the result interpretable.

A lineage is a combination, never one marker

No single antigen identifies a population: markers are shared across lineages, appear on activation and disappear on maturation. A panel identifies a cell by what it has and what it lacks, and the exclusion markers are as important as the inclusion ones.

Write the definition down as a gating sequence with the exclusions in it, publish it with the clones, and keep it constant across a study. A population defined differently between experiments is not the same population.

Granulocytes, activation and the markers that move

Several granulocyte markers are stored in granules and appear on the surface when the cell is activated, so they report state rather than identity, and they can be up-regulated by the sample handling itself. Delay, temperature and even vigorous pipetting change them.

That makes pre-analytical discipline part of the measurement: fixed time to processing, consistent temperature, gentle handling, and a sample processed identically as a reference. A rise in an activation marker is a handling difference until proven otherwise.

Dendritic cell subsets are defined by exclusion

Dendritic cells are rare and their subsets are defined by excluding other lineages and then dividing what remains on a small number of positive markers. That makes them one of the hardest panels to build and one where a poor exclusion step produces a subset that is mostly something else.

Because they are rare, the number of events acquired matters as much as the panel: a subset at a fraction of a percent needs a large acquisition before its frequency is measured rather than estimated.

Species differences are not cosmetic

Mouse and human panels use different markers for the same populations, and some markers behave differently or do not exist in the other species. A panel translated marker by marker between species usually identifies something different.

Use the established panel for the species, cite it, and confirm the populations against a known control tissue or organ. Where a mouse strain lacks a marker allele, the panel has to account for that too, which is a common and easily missed source of a missing population.

A cxadr antibody and a junctional receptor

CXADR, the coxsackie and adenovirus receptor, sits at epithelial junctions, so a cxadr antibody gives a junctional pattern and is read in barrier and viral entry work. It is a transmembrane protein with several isoforms, so the epitope decides which are detected, and the junctional line rather than a diffuse membrane signal is what says the stain worked.

An enpp1 antibody and an ectoenzyme

ENPP1 is a surface enzyme that hydrolyses nucleotides and is studied in mineralisation and in innate signalling, so an enpp1 antibody reports the protein while the activity readout is a substrate assay with an inhibitor control. It is heavily glycosylated, giving a broad band, and it dimerises, which is why a non reducing gel is sometimes run beside the standard one.

An lrp1 antibody and a very large receptor

LRP1 is a large endocytic receptor cleaved into two chains that remain associated, so an lrp1 antibody has to say which chain it sees and a reducing gel separates them. The receptor binds dozens of ligands, so a functional claim needs the ligand named. Its size makes transfer the usual failure on a blot rather than the antibody itself.

An ager antibody, and the receptor also called RAGE

AGER is the gene for the receptor commonly written RAGE, so an ager antibody and a rage antibody are the same target under two conventions, which splits a catalogue search. The soluble decoy form and the membrane receptor are separate species, and which one an assay reports is the question that decides a clinical figure.

An adam10 antibody and the sheddase beside ADAM17

ADAM10 sheds a partly overlapping set of substrates with its better known relative, so an adam10 antibody is read with that relative rather than alone when a shedding event is being attributed. It is processed from a proenzyme, so only the mature form is active and the expected masses belong in the method. Selective inhibitors are what separate the two functionally.

Common questions

Are two antibodies against the same CD antigen interchangeable?

No. They may recognise different epitopes, tolerate fixation differently and separate populations differently. The clone is the product, which is why published panels cite clones rather than CD numbers alone.

What does a cd45 antibody do in a panel?

It separates leucocytes from debris, red cells and non-haematopoietic material, which is why it is the usual backbone marker. Getting it right makes every other gate in the panel cleaner.

Why is a CD44 antibody harder to interpret than a lineage marker?

Because it is broadly expressed and its level changes with cell state rather than identity. It should be read as a quantitative measure against a control, not as a positive or negative gate.

Do I need to re-titrate when the lot changes?

Yes, and it takes an afternoon. Conjugate lot changes shift the optimal concentration, and a panel that drifts across a study is usually a lot change nobody re-titrated.

Can I use a research clone as a therapeutic comparator?

As a positive control or a blocking reagent, yes. As an equivalent product, no: formulation, endotoxin specification and release testing differ, and only research use is supported.

Can one marker identify a population?

No. Markers are shared across lineages, appear on activation and disappear with maturation. A lineage is a combination including exclusions, written down as a gating sequence with its clones.

Can I translate a human panel to mouse?

Not marker by marker. Different markers define the same populations in the two species and some do not exist in the other. Use the established panel for the species and confirm against a known control tissue.

Browse by service class

• Compare Gene synthesis on advertised prices